

**Supplementary Table S1.** Basic demographic and clinical data of 30 healthcare workers who received BNT162b2 mRNA COVID-19 vaccine and were followed up to 8 months.

	<b>Subject ID</b>	<b>Gender</b>	<b>COVID-19 severity</b>
<b>COVID-19 recovered individuals</b>	R1	male	mild
	R2	female	mild
	R3	female	severe
	R4	female	mild
	R5	male	moderate
	R6	male	mild
	R7	female	mild
	R8	male	moderate
	R9	female	mild
	R10	female	mild
	R11	male	mild
	R12	male	critical
	R13	male	critical
	R14	female	mild
	R15	female	mild
Mean±SD	-	-	-
<b>Naïve individuals</b>	N1	male	na
	N2	female	na
	N3	male	na
	N4	female	na
	N5	female	na
	N6	female	na
	N7	male	na
	N8	female	na
	N9	male	na
	N10	male	na
	N11	male	na
	N12	female	na
	N13	female	na
	N14	female	na
	N15	male	na
Mean±SD	-	-	-

*na denotes not applicable*

**Supplementary Table S2.** Basic demographic and clinical data of 125 healthcare workers who received BNT162b2 mRNA COVID-19 vaccine and were followed up to 6 months.

	<b>COVID-19 recovered individuals</b>	<b>Naïve individuals</b>
<b>No. subjects</b>	39	86
<b>Age (years)</b> Mean±SD	50.4±11.3	45.5±14.3
<b>Gender</b>		
- Male, n (%)	12 (31.6)	39 (45.3)
- Female, n (%)	26 (68.4)	47 (54.6)
<b>COVID-19 severity</b>		Na
- Asymptomatic/mild, n (%)	31 (79.5)	
- Moderate, n (%)	2 (5.1)	
- Severe, n (%)	2 (5.1)	
- Critical, n (%)	4 (10.3)	
<b>Time from COVID-19 diagnosis<sup>o</sup> to first vaccine dose (days)</b>		na
- Mean±SD	230.4±93.6	

*na* denotes *not applicable*

**Supplementary Table S3.** Basic demographic and clinical data of 14 healthcare workers who received booster BNT162b2 mRNA COVID-19 vaccine injection and were followed up to one week.

	<b>Subject ID</b>	<b>Gender</b>	<b>COVID-19 severity</b>
<b>COVID-19 recovered individuals receiving booster dose</b>	RB1	female	severe
	RB2	female	mild
	RB3	male	critical
	RB4	male	moderate
	RB5	female	mild
	RB6	male	critical
	RB7	female	mild
Mean±SD	-	-	-
<b>Naïve individuals receiving booster dose</b>	NB1	female	na
	NB2	female	na
	NB3	male	na
	NB4	female	na
	NB5	male	na
	NB6	male	na
	NB7	male	na
Mean±SD	-	-	-

*na denotes not applicable*

**Supplementary Table S4.** Basic demographic and clinical data of 14 individuals who were hospitalized for COVID-19 between March and April 2020 and followed up to 12 months from discharge.

	<b>Subject ID</b>	<b>Gender</b>	<b>COVID-19 severity</b>
<b>Unvaccinated COVID-19 recovered individuals</b>	U1	male	moderate
	U2	male	moderate
	U3	male	severe
	U4	female	severe
	U5	male	moderate
	U6	male	severe
	U7	male	critical
	U8	male	critical
	U9	female	severe
	U10	female	critical
	U11	female	moderate
	U12	female	moderate
	U13	female	moderate
	U14	male	critical
Mean±SD	-	-	-

**Supplementary Table S5. List of all fluorochrome mAbs used for flow cytometric analysis of antigen specific T cells.**

<b>Antigen</b>	<b>Flurochrome</b>	<b>Clone</b>	<b>Company</b>
TNF- $\alpha$	FITC	6401.1111	BDBioscience
CD154	PE	TRAP1	BDBioscience
CD3	PerCP	SK7	BDBioscience
CD4	PE-Cy7	SK3	Invitrogen
CD8	Super Bright 600	SK1	eBioscience™
IL-2	APC	MQ1-17H12	BDBioscience
IFN- $\gamma$	Pacific Blue	B27	BioLegend
L/D	Fixable Viability Stain 780		BDBioscience

**Supplementary Table S6. List of all fluoro-chrome mAbs used for flow cytometric analysis of antigen specific B cells.**

<b>Antigen</b>	<b>Fluoro-chrome</b>	<b>Clone</b>	<b>Company</b>
CD19	APC-Vio770	LT19	Miltenyi
CD27	VioBright FITC	M-T271	Miltenyi
IgA	VioGreen	IS11-8E10	Miltenyi
IgG	VioBlue	IS11-3B2.2.3	Miltenyi
CD14	PerCP	TÜK4	Miltenyi
IgM	APC	PJ2-22H3	Miltenyi
CD3	PerCP	BW264/56	Miltenyi
7AAD			Miltenyi
Spike	PE		Miltenyi
Spike	PE-Vio770		Miltenyi